DrugPatentWatch Database Preview

Details for Patent: 9,018,243

« Back to Dashboard

Which drugs does patent 9,018,243 protect, and when does it expire?

Patent 9,018,243 protects OTEZLA and is included in one NDA.

This patent has sixty-six patent family members in twenty countries.

Summary for Patent: 9,018,243

Title:	Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoi- soindoline-1,3-dione, compositions thereof, and uses thereof
Abstract:	Solid forms comprising (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoi- soindoline-1,3-dione, compositions comprising the solid forms, methods of making the solid forms and methods of their use are disclosed. The methods include methods of treating and/or preventing disorders ameliorated by the reduction of levels of TNF-.alpha. or the inhibition of PDE4.
Inventor(s):	Muller; George W. (Rancho Santa Fe, CA), Schafer; Peter H. (Belle Mead, NJ), Man; Hon-Wah (Princeton, NJ), Ge; Chuansheng (Belle Mead, NJ), Xu; Jean (Warren, NJ)
Assignee:	Celgene Corporation (Summit, NJ)
Application Number:	14/102,407
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 9,018,243
Patent Claim Types: see list of patent claims	Use;

Drugs Protected by US Patent 9,018,243

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Celgene Corp	OTEZLA	apremilast	TABLET;ORAL	205437-001	Mar 21, 2014		RX	Yes	No						USE OF OTEZLA (APREMILAST) FOR THE TREATMENT OF PSORIASIS
Celgene Corp	OTEZLA	apremilast	TABLET;ORAL	205437-001	Mar 21, 2014		RX	Yes	No						USE OF OTEZLA (APREMILAST) FOR THE TREATMENT OF PSORIATIC ARTHRITIS
Celgene Corp	OTEZLA	apremilast	TABLET;ORAL	205437-002	Mar 21, 2014		RX	Yes	No						USE OF OTEZLA (APREMILAST) FOR THE TREATMENT OF PSORIASIS
Celgene Corp	OTEZLA	apremilast	TABLET;ORAL	205437-002	Mar 21, 2014		RX	Yes	No						USE OF OTEZLA (APREMILAST) FOR THE TREATMENT OF PSORIATIC ARTHRITIS
Celgene Corp	OTEZLA	apremilast	TABLET;ORAL	205437-003	Mar 21, 2014		RX	Yes	Yes						USE OF OTEZLA (APREMILAST) FOR THE TREATMENT OF PSORIATIC ARTHRITIS
Celgene Corp	OTEZLA	apremilast	TABLET;ORAL	205437-003	Mar 21, 2014		RX	Yes	Yes						USE OF OTEZLA (APREMILAST) FOR THE TREATMENT OF PSORIASIS

International Family Members for US Patent 9,018,243

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	440599
Australia	2003224729
Canada	2479666
Canada	2756798
China	100427085
China	101683334
China	1652772